Screener
Arcus Biosciences RCUS Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue ($11 and $35 to a related party) | 19 | 35 |
| Other current liabilities | 145 | 154 |
| Total current liabilities | 198 | 231 |
| Deferred revenue, noncurrent ($19 and $43 to a related party) | 37 | 43 |
| Long-term debt | 101 | 99 |
| Other noncurrent liabilities | 124 | 135 |
| Commitments | ||
| Stockholders’ equity: |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's contract liabilities, non-current?
- Arcus Biosciences (RCUS) reported contract liabilities, non-current of $37M in Q2 2026.
- How has Arcus Biosciences's contract liabilities, non-current changed year-over-year?
- Arcus Biosciences's contract liabilities, non-current decreased by 38.3% year-over-year, from $60M to $37M.
- What is the long-term trend for Arcus Biosciences's contract liabilities, non-current?
- Over 5 years (2020 to 2025), Arcus Biosciences's contract liabilities, non-current has grown at a -20.2% compound annual growth rate (CAGR), from $132.53M to $43M.
- What does contract liabilities, non-current mean?
- Obligation to transfer goods or services for which payment has been received, expected to be satisfied beyond one year.
Ask your AI about Arcus Biosciences's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude